JO
HQL

John Overdeck’s abrdn Life Sciences Investors HQL Stock Holding History

John Overdeck’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,540
Closed -$321K – 3157
2024
Q1 		$321K Buy
+23,540
New +$326K ﹤0.01% 2536

Other funds holding HQL

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $1.03B AUM 1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.15B AUM 12.28% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $30.4M AUM 3.41% 1-Year Est. Return

John Overdeck's HQL Position: Q2 2024 in Review

John Overdeck sold out of abrdn Life Sciences Investors (HQL) in Q2 2024, closing a stake of 23,540 shares — an estimated $321K sold.

John Overdeck first reported a position in HQL in Q1 2024 and held it in 1 quarter. The position peaked at $321K in Q1 2024. 75 funds tracked by Wall St. Rank hold HQL as of Q2 2024.

  • John Overdeck reported no remaining abrdn Life Sciences Investors position as of Q2 2024 after selling out during the quarter.
  • John Overdeck sold 23,540 abrdn Life Sciences Investors shares in Q2 2024, an estimated $321K.
  • John Overdeck first reported a position in abrdn Life Sciences Investors in Q1 2024 and held it in 1 quarter.
  • John Overdeck's abrdn Life Sciences Investors position peaked at $321K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.